Suven Life Sciences secured three product patents (two from Eurasia and one from Canada) corresponding to the new chemical entities for the treatment of disorders associated with Neurodegenerative diseases. The patents are valid through 2027. The company's stocks rallied 5% on the news.
In an interview to CNBC-TV18, Venkat Jasti, chief executive officer, Suven Life Sciences gives the details of the patents received. He says it will take atleast three to four years before any activity on the patents' starts. "The patents that we have got are mainly for cognition based disorders such as Alzheimer's and schizophrenia. The market potential is huge," he adds.
Below is the edited transcript of Jasti's interview to CNBC-TV18.
Q: You recently got approvals from Eurasia and Canada for some of your chemical entities. Can you tell us what they add up to in terms of sales?
A: The patents that we have got are mainly for cognition based disorders such as Alzheimer's and schizophrenia. The market potential is huge. We are about to enter into phase II A clinical trial this year. So, it will take another three to four years before one sees any activity in this. Until then, I cannot comment on our revenue generation. Market potential is huge because it has a huge unmet medical need.
Q: Have you entered into any agreement with any of the leading pharmaceutical companies globally to carry on these phased trials?
A: No, not yet. As of now, we are going ahead on our own. We are still trying to align with some of the big pharma companies. However, big pharma companies are risk averse and they want to have compounds that are in the late phases of development; that is, after proof-of-concept. Hence, we have to go ahead and do the proof-of-concept. About 400 patients will be involved in this.
More to come.